SECTOR : Biotech
ENTRY DATE : 2006
EXIT DATE : 2009
BUSINESS : Venture Capital
Development of innovative and unique humanised therapeutic antibodies.
Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.
PRESS RELEASE(S) :
28/03/2006• PanGenetics BV agrees to a second capital increase with ABN AMRO, Index Ventures and Crédit Agricole Private Equity